Financial Data and Key Metrics Changes - The company reported record results in Q3 2025, with Pega Cloud ACV, revenue, and free cash flow all reaching new highs, showing continued acceleration [22] - Annual contract value (ACV) grew 14% year over year, with over $147 million in net new ACV added in constant currency during the first nine months of 2025, exceeding the total net new ACV added in all of 2024 [22][28] - Pega Cloud grew 27% year over year, representing the fastest-growing component of Pega's total ACV [22][23] Business Line Data and Key Metrics Changes - Pega Cloud was highlighted as a major growth driver, with margins approaching 80% in Q3 [23] - The unique approach of utilizing AI in the design phase while leveraging predictable workflows at runtime continues to differentiate the company in the market [24] Market Data and Key Metrics Changes - The company is experiencing strong momentum as clients shift from experimentation to execution, embracing Pega GenAI Blueprint for enterprise transformation [11][24] - The federal sector is undergoing changes, with IT modernization being a bipartisan focus area, indicating potential growth opportunities in government contracts [78] Company Strategy and Development Direction - The company aims to be the workflow automation and AI orchestration platform of choice for enterprises, leveraging its unique architecture and solutions [11][17] - Pega GenAI Blueprint is positioned as a game changer, enhancing client engagement and accelerating the time from design to production [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing the distinctive architecture and the unrivaled Blueprint solution as key advantages in handling modern enterprise complexities [20] - The company is confident that its approach to AI will resonate with prospects, clients, and partners, emphasizing the importance of predictability in AI applications [21] Other Important Information - The company completed its largest share repurchase quarter ever, purchasing $393 million of Pega stock, demonstrating confidence in long-term business value [27] - The company remains debt-free after repaying its convertible senior notes in March 2025 [27] Q&A Session Summary Question: What drove the much better ACV and acceleration versus your expectation of it slowing down? - Management indicated that the positive impact of Pega GenAI Blueprint on business performance was a key driver of the better-than-expected ACV growth [31] Question: What is the current state of the federal business and deal environment? - Management noted that while the federal space has faced challenges, long-term projects continue to progress, and IT modernization remains a priority [33][78] Question: Can you discuss the early feedback on the new predictable AI agents? - Management highlighted that the understanding of the differences in their AI agents is resonating with customers, emphasizing the predictability of their approach compared to competitors [37][38] Question: How is pricing evolving in the industry? - Management stated that they are ahead of competitors in moving towards work-based pricing, aligning vendor and customer incentives [58][62] Question: Are you seeing any new players in the space? - Management acknowledged peripheral competitors but emphasized the importance of a center-out approach for true omnichannel capabilities [63] Question: Are customers integrating the new AI agents into production? - Management confirmed that many new implementations in the last six months are in production, showcasing the enthusiasm for the Blueprint approach [67][70]

Financial Data and Key Metrics Changes - In Q3 2025, total company operational sales grew 19%, and organic sales grew 15%, exceeding the guidance range of 12%-14% [6][22] - Q3 adjusted EPS was $0.75, reflecting a 19% increase and surpassing the guidance range of $0.70-$0.72 [6][22] - Adjusted operating margin for Q3 was 28%, with an expectation to expand full-year adjusted operating margin by approximately 100 basis points [6][23][26] Business Line Data and Key Metrics Changes - Urology sales grew 27% operationally and 5% organically, driven by international business and Global Stone Management [9] - Endoscopy grew 9%, with double-digit growth in key products [10] - Neuromodulation sales increased by 9%, supported by strong performance in the brain franchise [10] - Peripheral interventions sales grew 16% operationally and 6% organically, with low double-digit growth in the U.S. [11] - Cardiology sales grew 23%, with interventional cardiology therapy sales growing 3% [14] Market Data and Key Metrics Changes - U.S. operational sales grew 27%, while Europe, Middle East, and Africa (EMEA) declined 2% due to specific headwinds [7][8] - Asia-Pacific grew 17% operationally, led by strong growth in Japan and China [8] - WATCHMAN sales grew 35%, reflecting strong market penetration and adoption [15][16] Company Strategy and Development Direction - The company is focused on strategic tuck-in M&A in high-growth adjacencies, with the recent agreement to acquire Nalu Medical to expand into peripheral nerve pain [11][24] - The company aims for 10%+ average organic revenue growth from 2026 to 2028, with a target of 70%-80% annual free cash flow conversion [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining above-market growth, with expectations for continued strong performance in the cardiovascular and MedSurg segments [6][7] - The company anticipates improvements in backorders and operational performance in Europe in the fourth quarter [8] - Management remains optimistic about the growth potential of WATCHMAN and electrophysiology, projecting a 20% CAGR over the long-range plan [32][48] Other Important Information - The company experienced a backorder of approximately $30 million due to an ERP system upgrade, impacting various business lines [8][76] - The company expects to close the acquisition of Nalu Medical in the first half of 2026 [11][24] Q&A Session Summary Question: Is WATCHMAN a key growth driver? - Management confirmed that WATCHMAN is a significant growth driver, with expectations for continued market expansion and strong performance [32] Question: What is the outlook for the China market? - Management indicated that the China business is performing well, with expectations for double-digit growth despite price pressures [39] Question: How will the new product cycle impact CRM growth? - Management expressed confidence in the upcoming product cycle, including the Denali platform and EMPOWER leadless pacemaker, to strengthen CRM growth [86] Question: What are the dynamics outside EP and WATCHMAN? - Management highlighted strong growth in other divisions, including neuromodulation and endoscopy, and emphasized ongoing investments in these areas [58]

Financial Data and Key Metrics Changes - The company reported record results in Q3 2025, with Pega Cloud Annual Contract Value (ACV), revenue, and free cash flow all reaching new highs, showing continued acceleration [22] - Annual contract value grew 14% year-over-year, with over $147 million in net new ACV added in constant currency during the first nine months of 2025, exceeding the total net new ACV added in the entire year of 2024 [22][28] - Pega Cloud grew 27% year-over-year, representing the fastest-growing component of Pega's total ACV [22][23] Business Line Data and Key Metrics Changes - Pega Cloud remains a major growth driver, with margins approaching 80% in Q3 [23] - The unique approach of utilizing AI in the design phase while leveraging predictable workflows at runtime continues to differentiate the company in the market [24] Market Data and Key Metrics Changes - The company is experiencing accelerated growth as more clients migrate to Pega Cloud, highlighting the increasing client focus on cloud-native architectures and solutions for AI adoption [23][28] - The majority of net new ACV is coming from Pega Cloud, indicating a shift towards a more scalable business model [24] Company Strategy and Development Direction - The company aims to be the workflow automation and AI orchestration platform of choice for enterprises, leveraging its unique architecture and solutions [11][20] - The introduction of Pega Blueprint is seen as a game changer, enabling faster and more reliable client engagement and project execution [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong momentum as clients shift from experimentation to execution with Pega Blueprint [11][20] - The company is focused on closing the year strong and continuing the momentum seen through 2025 [28] Other Important Information - The company completed its largest share repurchase quarter ever, purchasing $393 million of Pega stock, demonstrating confidence in long-term business value [27] - The company remains debt-free after repaying convertible senior notes in March 2025 [27] Q&A Session Summary Question: What drove the much better ACV and acceleration versus your expectation of it slowing down? - Management indicated that the positive impact of Pega Blueprint on business performance was a key driver of the better-than-expected ACV growth [31] Question: What are you seeing on the federal side of the business? - Management noted that while the federal space has faced challenges, long-term projects continue to move forward, and IT modernization remains a bipartisan focus area [33][78] Question: Can you talk about the early feedback on the new predictable AI agents? - Management highlighted that the understanding of the differences in their AI agents is resonating with customers, emphasizing predictability and reliability [37][38] Question: How is pricing evolving in the industry? - Management stated that the company is ahead of competitors in moving towards work-based pricing rather than seat-based pricing, aligning vendor and customer incentives [58][61] Question: Are you seeing any new players in this space? - Management acknowledged seeing new players on the periphery but emphasized the importance of a center-out approach for true omnichannel capabilities [63] Question: Are customers integrating the new Blueprint capabilities into production? - Management confirmed that Blueprint is responsible for many new implementations, with numerous projects already in production [67][70]

Financial Data and Key Metrics Changes - Pegasystems reported record results in Q3 2025, with Pega Cloud ACV, revenue, and free cash flow all reaching new highs, indicating continued acceleration in performance [19][20] - Annual contract value (ACV) grew 14% year over year, with over $147 million in net new ACV added in constant currency during the first nine months of 2025, surpassing the total net new ACV added in all of 2024 [19][20] - Pega Cloud was the standout performer, growing 27% year over year and representing the fastest-growing component of Pega's total ACV [20][21] Business Line Data and Key Metrics Changes - Pega Cloud margins approached 80% in Q3, reflecting the scalability of the platform and increasing client focus on cloud-native architectures [21] - The unique approach of utilizing AI in the design phase while leveraging predictable workflows at runtime continues to differentiate Pegasystems in the market [22] Market Data and Key Metrics Changes - The demand for Pega's solutions is driven by clients migrating to Pega Cloud, which is becoming the foundation for mission-critical workloads [21][26] - The company is experiencing accelerated growth as clients shift from experimentation to execution, particularly with the adoption of Pega GenAI Blueprint [10][22] Company Strategy and Development Direction - Pegasystems aims to be the workflow automation and AI orchestration platform of choice for enterprises, leveraging its unique architecture and solutions [10][15] - The introduction of Pega GenAI Blueprint is seen as a game changer, enhancing client engagement and shortening sales cycles [11][12] - The company is focused on closing the year strong and continuing the momentum seen throughout 2025 [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the structural advantages of their unique architecture and the Pega GenAI Blueprint [17][18] - The company is confident that its approach to AI will resonate with prospects, clients, and partners, emphasizing the importance of reliability at runtime [18] Other Important Information - Pegasystems completed its largest share repurchase quarter ever, purchasing $393 million of stock, demonstrating confidence in the long-term value of the business [24][25] - The company remains debt-free after repaying its convertible senior notes in March 2025 [25] Q&A Session Summary Question: What drove the much better ACV and acceleration versus your expectation of it slowing down? - Management indicated that the positive impact of Pega GenAI Blueprint on business performance was a key driver of the better-than-expected ACV growth [29] Question: What is the deal environment like in the federal space? - Management noted that while the federal space has faced challenges, long-term projects continue to move forward, and IT modernization remains a priority [31][70] Question: Can you talk about the early feedback on the new predictable AI agents? - Management highlighted that the understanding of the differences in their AI agents is resonating with customers, emphasizing predictability and reliability [33][34] Question: How is the legacy transformation opportunity tracking? - Management stated that any acceleration in growth is largely tied to Pega GenAI Blueprint and legacy transformation opportunities [65] Question: What is the impact of cloud migration on term license revenue? - Management explained that while term license revenue may decline over time due to cloud migration, overall growth is driven by increased client spending [80]

Financial Data and Key Metrics Changes - In Q3 2025, total company operational sales grew 19%, and organic sales grew 15%, exceeding the guidance range of 12% to 14% [5][20] - Q3 adjusted EPS was $0.75, reflecting a 19% increase and surpassing the guidance range of $0.70 to $0.72 [5][20] - Adjusted operating margin for Q3 was 28%, with an expected full-year adjusted EPS guidance of $3.02 to $3.04, representing growth of 20% to 21% [6][25] Business Line Data and Key Metrics Changes - Urology sales grew 27% operationally and 5% organically, driven by international business and Global Stone Management [8] - Endoscopy grew 9%, with double-digit growth in key products, particularly in the U.S. [9] - Neuromodulation sales increased by 9%, supported by strong performance in the brain franchise and pain franchise [9][10] - Cardiology sales grew 23%, with interventional cardiology therapy sales growing 3% [12] Market Data and Key Metrics Changes - U.S. operational sales grew 27%, while Europe, Middle East, and Africa (EMEA) declined 2% due to specific headwinds [6][7] - Asia-Pacific grew 17% operationally, led by strong growth in Japan and China [7][8] - Watchman sales grew 35%, reflecting strong uptake in the U.S. [14] Company Strategy and Development Direction - The company is focused on strategic tuck-in M&A in high-growth adjacencies, with recent acquisitions including Nalu Medical [20][24] - The company aims for 10% plus average organic revenue growth from 2026 to 2028, with a target of 50 basis points of annual adjusted operating margin expansion [26] - The company is investing in innovative solutions across both AF and non-AF segments to outpace market growth [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining above-market growth, particularly in the U.S. and Asia-Pacific [5][6] - The company anticipates improvements in backorders and expects to recover from ERP implementation challenges in Europe [7][10] - Management remains optimistic about the growth potential of Watchman and EP technologies, projecting a 20% CAGR over the long-range plan [32][44] Other Important Information - The company expects full-year 2025 reported revenue growth of approximately 20%, with operational revenue growth of about 19% [24] - Free cash flow for Q3 was $1.163 billion, with expectations of approximately $3.5 billion for the full year [23] Q&A Session Summary Question: Is Watchman a key growth driver? - Management confirmed that Watchman is a significant growth driver, with expectations of continued strong performance and market penetration [30][32] Question: What is the outlook for the China market? - Management indicated that the China business is performing well, with expectations of double-digit growth despite VBP price pressures [36][38] Question: How will the new product cycle impact CRM growth? - Management expressed confidence in the upcoming Denali platform and Empower leadless pacemaker, which are expected to enhance growth in the CRM segment [78][80] Question: What are the drivers for growth outside of EP and Watchman? - Management highlighted strong performance in neuromodulation, endoscopy, and the potential for Urology to improve in 2026 [55][56]

Financial Data and Key Metrics Changes - In Q3 2025, total company operational sales grew 19% and organic sales grew 15%, exceeding the guidance range of 12% to 14% [6][27] - Q3 adjusted EPS was $0.75, a 19% increase, surpassing the guidance range of $0.70 to $0.72 [6][27] - Adjusted operating margin for Q3 was 28%, an increase of 80 basis points year-over-year [27][28] Business Line Data and Key Metrics Changes - Urology sales grew 27% operationally and 5% organically, driven by international business and global stone management franchise [10] - Endoscopy sales increased by 9%, with double-digit growth in key products [12] - Neuromodulation sales grew 9%, supported by strong performance in the brain franchise [12] - Peripheral Interventions sales grew 16% operationally and 6% organically, with low single-digit growth in arterial business impacted by China VBP [14] Market Data and Key Metrics Changes - U.S. operational sales grew 27%, with strong performance across cardiovascular businesses, endoscopy, and neuromodulation [8] - Europe, Middle East, and Africa (EMEA) saw a decline of 2% operationally due to specific headwinds, but excluding these, growth would have been in high single digits [8] - Asia Pacific grew 17% operationally, led by strong growth in Japan and China [9] Company Strategy and Development Direction - The company is focused on expanding its innovative portfolio and maintaining above-market growth, with a full-year organic growth guidance raised to approximately 15.5% [7][30] - The acquisition of Nalu Medical is expected to enhance the company's portfolio in the pain management space [13][92] - The company aims to be market share leaders in electrophysiology (EP) and continues to invest in innovative solutions to drive growth [24][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained above-market growth, particularly in the U.S. and China, despite challenges in EMEA [8][46] - The company anticipates continued strong performance in the WATCHMAN market, projecting approximately 20% growth over the long-range plan [39][50] - Management noted that there are no signals of procedural pull-forward due to external pressures, indicating consistent demand [44] Other Important Information - The company expects full-year 2025 reported revenue growth of approximately 20%, with operational revenue growth of about 19% [30] - Adjusted gross margin for Q3 was 71%, reflecting a 60 basis point improvement year-over-year [28] - Free cash flow for Q3 was $1,163 million, with expectations of approximately $3,500 million for the full year [29] Q&A Session Summary Question: Is WATCHMAN a key growth driver? - Management confirmed that WATCHMAN is a significant growth driver, with expectations of continued market expansion and strong adoption rates [36][39] Question: What is the outlook for the China business? - Management indicated that the China business is performing well, with mid-teens growth expected to continue despite VBP pressures [42][46] Question: How will the new product cycle impact CRM growth? - Management expressed confidence in the upcoming product cycle, including the Denali platform and leadless pacemaker, which are expected to enhance growth in the CRM segment [98][100] Question: What is the impact of the $30 million back order? - The back order primarily affected the MedSurg and Peripheral Interventions businesses, but management expects it to normalize by the end of the year [85][86]

Travel + Leisure (NYSE:TNL) Q3 2025 Earnings Call October 22, 2025 08:00 AM ET Speaker1Greetings and welcome to the Travel + Leisure Co. Q3 2025 earnings conference call and webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. You may be placed into the question queue at any time by pressing star one on your telephone keypad, and we ask that you please ask one question and one follow-up, then return to the queue. If anyone shou ...

Financial Data and Key Metrics Changes - Pegasystems reported record results in Q3 2025, with Pega Cloud annual contract value (ACV), revenue, and free cash flow all reaching new highs, reflecting a 14% year-over-year growth in ACV [29][30] - Free cash flow increased by 38% year-over-year, totaling $338 million for the first nine months of 2025 [35][36] - Pega Cloud ACV grew 27% year-over-year, indicating strong demand for cloud-native architectures and solutions [30][31] Business Line Data and Key Metrics Changes - The standout performer was Pega Cloud, which significantly contributed to the overall ACV growth, with over 85% of ACV growth this year generated from Pega Cloud [30][38] - The company’s unique approach of utilizing AI in the design phase while leveraging predictable workflows at runtime continues to differentiate it in the market [32] Market Data and Key Metrics Changes - The company is experiencing accelerated growth and momentum as clients migrate to Pega Cloud, with margins approaching 80% in Q3 [31] - The federal sector has seen changes due to government shutdowns, but long-term projects remain strategic and are expected to continue despite short-term disruptions [42][91] Company Strategy and Development Direction - Pegasystems aims to be the workflow automation and AI orchestration platform of choice for enterprises, leveraging its unique architecture and AI strategy [15][24] - The introduction of Pega Blueprint is seen as a game changer, enhancing client engagement and accelerating the time from design to production [17][20] - The company is focused on application modernization and legacy transformation, with significant energy around new features that facilitate these processes [66] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong momentum as clients shift from experimentation to execution with Pega Blueprint [15][27] - The company is confident in its business model and strategy, emphasizing the importance of ACV as a measure of business momentum and durability [63][64] Other Important Information - Pegasystems completed its largest share repurchase quarter ever, purchasing approximately $393 million worth of stock [36] - The company remains debt-free after repaying its convertible senior notes in March 2025 [37] Q&A Session Summary Question: What drove the much better ACV and acceleration versus expectations? - Management indicated that the positive impact of Pega Blueprint on business performance was a key driver of the better-than-expected ACV growth [41] Question: What is the deal environment on the federal side? - Management noted that while the federal space has faced challenges, long-term projects remain strategic and are expected to continue [42] Question: Can you discuss the early feedback on the new Predictable AI agents? - Management highlighted that the differentiation of their agents is resonating with customers, emphasizing predictability and efficiency in design and execution [46][47] Question: How is pricing evolving in the industry? - Management stated that Pegasystems is ahead of competitors by moving towards work-based pricing, aligning vendor and customer incentives [70][72] Question: Are you seeing any new players in the space? - Management acknowledged the presence of new players but emphasized the importance of a comprehensive orchestration layer that Pegasystems provides [75] Question: Are customers integrating the new Blueprint capabilities into production? - Management confirmed that Blueprint is responsible for many new implementations, with numerous clients already in production [80][82]

Financial Data and Key Metrics Changes - GE Vernova reported a 10% organic revenue growth in Q3, with adjusted EBITDA more than tripling year-over-year to $811 million, and EBITDA margins expanded by 600 basis points [28][30][29] - The total equipment backlog grew to $54 billion, an increase of $11 billion year-to-date, with a services backlog of approximately $81 billion, reflecting a year-over-year increase of over $5 billion [26][29] - Free cash flow generation was approximately $730 million in Q3, with a year-to-date total of nearly $2 billion [32][30] Business Line Data and Key Metrics Changes - The electrification segment saw a revenue increase of over 30% with margins expanding to over 15%, driven by strong demand across multiple regions [27][38] - Power orders grew by 50%, with gas power equipment orders more than doubling year-over-year, leading to a revenue increase of 14% [33][30] - Wind revenue decreased by 9% due to the absence of a settlement from an offshore contract cancellation, but onshore services orders were up 27% year-to-date [35][36] Market Data and Key Metrics Changes - The electrification equipment market in North America is expected to grow at a compounded growth rate of approximately 10%, doubling in size by 2030 [10] - Significant investment in electrification is being driven by increased electricity demand, grid stability needs, and the energy transition [11] - The backlog for Prolec GE was approximately $4 billion at the end of Q2, with expectations for low double-digit revenue growth driven by volume and pricing [13] Company Strategy and Development Direction - The acquisition of Prolec GE for $5.275 billion is aimed at consolidating GE Vernova's position in the grid equipment market, particularly in transformers for North America [5][7] - The company plans to fund the acquisition with a mix of cash and debt while maintaining an investment-grade balance sheet [15] - GE Vernova aims to leverage synergies from the acquisition to enhance operational efficiency and expand product offerings, particularly in low and medium voltage technologies [10][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of the electrification segment, citing strong demand from hyperscalers and data centers [22][19] - The company anticipates continued strength in gas-powered demand and pricing, with expectations to approach 70 gigawatts of contractual gas power commitments by the end of 2025 [20][19] - Management highlighted the importance of maintaining reliability and modernizing aging infrastructure to meet increasing electricity demand [11] Other Important Information - GE Vernova is committed to returning at least one-third of cash generated to shareholders while pursuing targeted M&A opportunities [42] - The company has repurchased over 6 million shares for approximately $2.2 billion year-to-date, reflecting confidence in its stock value [26][32] - The company is investing in AI and automation to enhance productivity and meet growing demand in gas turbine controls engineering [25] Q&A Session Summary Question: Visibility into 2028 targets for Prolec GE acquisition - Management expressed confidence in the 2028 targets due to existing backlog and framework agreements with utilities, which are expected to drive growth [47][49] Question: Mix and capacity for Prolec GE - Management discussed ongoing investments in capacity and the potential for integrated solutions with data centers, emphasizing a focus on medium and low voltage technologies [54][56] Question: Pricing trends for gas turbines - Management acknowledged that while pricing for U.S. gas turbines is currently strong, there is a mix dynamic affecting the overall pricing perception [59][60] Question: Power equipment dollar orders versus gigawatt orders - Management clarified that the positive delta in dollar growth versus gigawatt growth is due to a mix of aero derivatives and heavy-duty gas turbines [63][64] Question: Structural opportunity for margins beyond 2028 - Management indicated that there is no reason to believe margins cannot exceed previous peak levels, citing a larger install base and a more profitable services business [70][72] Question: Cost synergy realization cadence - Management stated that cost synergies are expected to be realized by 2028, with initial savings anticipated to flow relatively soon as teams begin discussions [77]

GE Vernova (NYSE:GEV) Q3 2025 Earnings Call October 22, 2025 07:30 AM ET Company ParticipantsMichael Lapides - VP of Investor RelationsAmit Mehrotra - Managing DirectorScott Strazik - CEONigel Coe - Managing DirectorMichael Blum - Managing DirectorAndy Kaplowitz - Managing DirectorKen Parks - CFOJoe Ritchie - Managing DirectorConference Call ParticipantsNicole DeBlase - AnalystJulian Mitchell - Equity Research AnalystMoses Sutton - Clean Energy Equity AnalystChris Dendrinos - Vice President and Equity Resea ...